{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=metformin+placebo", "query": { "intervention": "metformin placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 421, "total_pages": 43, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=metformin+placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-18T18:28:18.415Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00712673", "title": "GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 680, "start_date": "2008-06", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-09-18T18:28:18.415Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00712673" }, { "nct_id": "NCT00976937", "title": "24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Lixisenatide (AVE0010)", "type": "DRUG" }, { "name": "Lixisenatide Placebo", "type": "DRUG" }, { "name": "Pen auto-injector", "type": "DEVICE" }, { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Sitagliptin Placebo", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 319, "start_date": "2009-08", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2016-10-11", "last_synced_at": "2026-09-18T18:28:18.415Z", "location_count": 21, "location_summary": "Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Paramount", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00976937" }, { "nct_id": "NCT04207944", "title": "The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "IPMN", "IPMN, Pancreatic" ], "interventions": [ { "name": "Sulindac 400 MG", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "21 Years to 85 Years" }, "enrollment_count": 100, "start_date": "2020-07-10", "completion_date": "2026-10-31", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-09-18T18:28:18.415Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04207944" }, { "nct_id": "NCT06829238", "title": "Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Systemic Inflammation", "Immune Dysregulation", "Injection Drug Use", "HIV" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Jynneos", "type": "BIOLOGICAL" }, { "name": "Capvaxvie", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 100, "start_date": "2025-04-07", "completion_date": "2029-11-30", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-09-18T18:28:18.415Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06829238" }, { "nct_id": "NCT06109311", "title": "A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Orforglipron", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 546, "start_date": "2023-11-10", "completion_date": "2025-09-15", "has_results": false, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-09-18T18:28:18.415Z", "location_count": 25, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Bryant, Arkansas + 22 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bryant", "state": "Arkansas" }, { "city": "Gardena", "state": "California" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06109311" }, { "nct_id": "NCT02500147", "title": "Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Polycystic Ovary Syndrome", "Non-Alcoholic Fatty Liver Disease", "Metabolic Syndrome" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "25 Years", "sex": "FEMALE", "summary": "13 Years to 25 Years · Female only" }, "enrollment_count": 3, "start_date": "2011-09-08", "completion_date": "2021-03-03", "has_results": true, "last_update_posted_date": "2025-07-02", "last_synced_at": "2026-09-18T18:28:18.415Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02500147" }, { "nct_id": "NCT01433913", "title": "Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Recurrent Prostate Cancer", "Stage I Prostate Cancer", "Stage IIA Prostate Cancer", "Stage IIB Prostate Cancer" ], "interventions": [ { "name": "metformin hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 20, "start_date": "2011-11", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2018-01-10", "last_synced_at": "2026-09-18T18:28:18.415Z", "location_count": 3, "location_summary": "Tucson, Arizona • Los Angeles, California", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01433913" }, { "nct_id": "NCT02656017", "title": "Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polycystic Kidney, Autosomal Dominant" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Kyongtae Ty Bae, M.D., Ph.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 97, "start_date": "2016-06-27", "completion_date": "2020-12-07", "has_results": true, "last_update_posted_date": "2022-08-09", "last_synced_at": "2026-09-18T18:28:18.415Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Boston, Massachusetts", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02656017" }, { "nct_id": "NCT00765817", "title": "Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "exenatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 261, "start_date": "2008-10", "completion_date": "2010-01", "has_results": true, "last_update_posted_date": "2016-10-24", "last_synced_at": "2026-09-18T18:28:18.415Z", "location_count": 40, "location_summary": "Peoria, Arizona • Phoenix, Arizona • Buena Park, California + 37 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Buena Park", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00765817" }, { "nct_id": "NCT00290940", "title": "Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "CS-917", "type": "DRUG" }, { "name": "metformin hydrochloride", "type": "DRUG" }, { "name": "pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 400, "start_date": "2006-01", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2007-09-11", "last_synced_at": "2026-09-18T18:28:18.415Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Northport, Alabama • Mesa, Arizona + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Northport", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290940" } ] }